Clinical Trials – Completed
Completed mesothelioma clinical trials have treated all study patients and finished collecting data. Once a study is completed, researchers examine the results. They will determine how and if to move forward with the treatment or technology at hand. Completed studies have improved mesothelioma survival.
Learn About Mesothelioma Clinical Trials in Our Free Guide
Completed Mesothelioma Clinical Trials
Clinical trials may help researchers better understand mesothelioma development and treatment. Clinical studies are considered completed once all treatments and follow-ups are done. This means researchers have collected the last data point from the last patient undergoing treatment. At this point, researchers examine the study results.
In the case of a clinical trial on mesothelioma treatment, this analysis helps answer many questions, including:
- Was the treatment effective?
- Did the benefits of the treatment outweigh the risks?
- Does the treatment require further study?
- Should the treatment be approved by the U.S. Food and Drug Administration (FDA)?
Once study coordinators have finished analyzing results, they may publish them in a medical journal. They may also share the study results in the trial’s ClinicalTrials.gov record.
For more information on clinical trials phases, processes, costs and enrollment, you can visit our Clinical Trials Overview page.
Mesothelioma Advances From Clinical Trials
Some completed clinical trials have tested treatments that substantially improved the prognosis for mesothelioma. Below are a few examples of noteworthy, completed mesothelioma clinical trials.
Study Name: CheckMate-743
Study Purpose: To evaluate an immunotherapy combination treatment compared to standard chemotherapy (cisplatin and pemetrexed)
New Treatment: Opdivo® (nivolumab) and Yervoy® (ipilimumab)
Type of Mesothelioma: Inoperable pleural mesothelioma
Most Important Result: Improved survival. Patients treated with Opdivo® and Yervoy® had a median survival of 18.1 months. Those treated with standard chemotherapy had a median survival of 14.1 months.
FDA Approval Status: The FDA approved Opdivo® and Yervoy® for treatment of inoperable pleural mesothelioma in October 2020.
Study Name: STELLAR
Study Purpose: To determine the effect of a novel, electric field-based treatment for pleural mesothelioma
New Treatment: Novo-TTF-100L System
Type of Mesothelioma: Inoperable pleural mesothelioma
Most Important Result: Encouraging survival without increased systemic toxicity. Patients had standard chemotherapy treatment followed by Novo-TTF treatment. Median overall survival was 18.2 months, which compares favorably to other treatment options.
FDA Approval Status: The Novo-TTF-100L System gained FDA approval in 2019. It is approved for the treatment of inoperable pleural mesothelioma in combination with standard chemotherapy. Since the approval, the treatment has become more widely available to mesothelioma patients.
Study Name: MAPS (Mesothelioma Avastin® Plus Pemetrexed-cisplatin Study)
Study Purpose: To determine the effect of an immunotherapy drug on the survival of patients also undergoing standard chemotherapy treatment
New Treatment: Avastin® (bevacizumab)
Type of Mesothelioma: Inoperable pleural mesothelioma
Most Important Result: Improved survival. Patients treated with chemotherapy and Avastin® had a median survival of 18.8 months. Those treated with chemotherapy alone had a median survival of 16.1 months.
FDA Approval Status: The manufacturer did not submit an application for FDA approval. However, experts say Avastin® may be offered to patients who can tolerate it.
Completed Mesothelioma Clinical Trials List
Provided below is a list of completed mesothelioma trials.
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 5/27/2026
Status: Completed
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 5/8/2026
Status: Completed
Conditions: Mesothelioma
Last Updated: 4/21/2026
Status: Completed
Conditions: Mesothelioma
Last Updated: 4/17/2026
Status: Completed
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Conditions: Mesothelioma
Last Updated: 4/13/2026
Status: Completed
Conditions: Mesothelioma
Last Updated: 3/27/2026
Status: Completed
Conditions: Mesothelioma
Last Updated: 3/5/2026
Status: Completed
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 1/22/2026
Status: Completed
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Conditions: Mesothelioma
Last Updated: 1/16/2026
Status: Completed
Conditions: Mesothelioma
Last Updated: 12/18/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 11/26/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 11/4/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 8/14/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 8/5/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/15/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/14/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/9/2025
Status: Completed
CART-meso in Mesothelin Expressing Cancers
Conditions: Mesothelioma
Last Updated: 6/29/2025
Status: Completed
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 6/24/2025
Status: Completed
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Conditions: Mesothelioma
Last Updated: 6/5/2025
Status: Completed
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Conditions: Mesothelioma
Last Updated: 5/13/2025
Status: Completed
CAR T Cells in Mesothelin Expressing Cancers
Conditions: Mesothelioma
Last Updated: 4/29/2025
Status: Completed
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Conditions: Mesothelioma
Last Updated: 2/19/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 2/7/2025
Status: Completed
The Registry of Oncology Outcomes Associated With Testing and Treatment
Conditions: Mesothelioma
Last Updated: 12/18/2024
Status: Completed
Sources
American Cancer Society. Deciding Whether to Be Part of a Clinical Trial. Updated August 2020.
American Cancer Society. What’s New in Malignant Mesothelioma Research? Updated May 2019.
Ghirardelli P, Franceschini D, et al. Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. Lung Cancer. February 2021;152:1-6. doi: 10.1016/j.lungcan.2020.11.022
Kindler HL, Ismaila N, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. May 2018;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394
Lau B, Boyer M, et al. Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes. Clinical Lung Cancer. July 2020;21(4):378-383.e1. doi: 10.1016/j.cllc.2020.01.007
Moffitt Cancer Center. Mesothelioma Clinical Trials.
National Cancer Institute. Paying for Clinical Trials. Updated February 2020.
National Cancer Institute. What Are Clinical Trials? Updated November 2021.
National Institute on Aging. Clinical Trials: Benefits, Risks, and Safety. Updated May 2017.
National Institute on Aging. Common Questions About Participating in Alzheimer’s and Related Dementias Research.
National Institutes of Health. NIH Clinical Research Trials and You: The Basics. Updated October 2017.
Novocure. FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma. May 2019.
Rintoul RC, Ritchie AJ, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. September 2014;384(9948):1118-27. doi: 10.1016/S0140-6736(14)60418-9
Warnock C, Lord K, et al. Patient experiences of participation in a radical thoracic surgical trial: findings from the Mesothelioma and Radical Surgery Trial 2 (MARS 2). Trials. October 2019;20(1):598. doi: 10.1186/s13063-019-3692-x
Yap TA, Nakagawa K, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. The Lancet Respiratory Medicine. June 2021;9(6):613-621. doi: 10.1016/S2213-2600(20)30515-4
Zalcman G, Mazieres J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. April 2016;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6
Free Mesothelioma Treatment Guide
Katy Moncivais, Ph.D., has more than 15 years of experience as a medical communicator. As the Medical Editor at Mesothelioma.com, she ensures our pages and posts present accurate, helpful information.
Tara Strand specializes in writing content about mesothelioma and asbestos. She focuses on topics like mesothelioma awareness, research, treatment, asbestos trust funds and other advocacy efforts.
